In cooperation with Xiangya Hospital of Central South University, Human Province, the company will launch a collection of stem cells isolated from maternal umbilical cords, which are cultivated and released on demand to the maternal donor and to Xiangya Hospital for stem cell clinical research and application. The stem cells will be stored at – 196 °C for 3 years free of cost, prolongation for payment is possible. Stem cell products can be used for the treatment of, e. g., endocrine diseases (premature ovarian failure, Intrauterine adhesions and menopausal syndrome, etc.), immune system diseases (systemic lupus erythematosus and ulcerative colitis), ischemic diseases (diabetic foot and ischemic cardiomyopathy), neurological diseases (Parkinson’s disease and stroke), degenerative osteoarthritis, type II diabetes, hypertension, and other.

China Bio news release, July 24, 2017